Alembic Pharmaceuticals has informed the exchange that the Company's joint venture, Aleor Dermaceuticals, has received US Food and Drug Administration (USFDA) Final Approval for Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation). In this regard the company has enclosed its press release on 4th March 2021.
The above information is a part of company’s filings submitted to BSE.